 The dynamic marketplace for life sciences and heath care continues to be shaped by forces on many fronts, spanning the spectrum from incremental to market-disrupting. In order to stay ahead in this changing marketplace, life sciences companies are addressing this idea of new, converged offerings. To deal with the convergence opportunities that market and technology changes offer, a number of companies will pursue creating combined products. In 2008 and beyond, these combination products are expected to provide life sciences companies with new avenues for growth and differentiation. Life sciences leaders considering convergence must make strategic decisions when choosing and managing their convergence pathway. Terry Hisey and John Rhodes address this issue of convergence and effective partnering in this Pharmaceutical Processing article. They explore the perils of partnering and the emergence of alliance networks in the industry. Portions of this article are excerpted from a new Deloitte Research report, “Managing the Pathways to Convergence in the life Sciences Industry.” Download the full report below. Printed with permission of the publisher. Related Content: Report: Managing Pathways to Convergence in the Life Sciences Industry
Report: The Future of the Life Sciences Industries: Strategies for Success in 2015
Webcast: Demystifying and Realizing the Potential of Drug, Device and Diagnostic Convergence
|